Clinical Trial

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This phase 1 study in Australia will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-03-21; most recent amendment 2025-03-11.
Status change: Recruiting → Active, Not Recruiting 2025-03-11
Status change: Not Yet Recruiting → Recruiting 2024-05-29
Trial Details
NCT Number NCT06335849
Lead Sponsor Guangzhou Patronus Biotech Co., Ltd.
Collaborators: Yantai Patronus Biotech Co., Ltd.
Conditions Herpes Zoster
Enrollment 48 participants
Start Date 2024-03-27
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-13